

Transfer of 16 Long-Listed Products in Japan

Tokyo, March 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Chairman: Sansei Oka, President and CEO: Jiro Mizukawa, “LTL Pharma”) have entered into an Asset Purchase Agreement, under which Astellas will transfer its marketing authorization of 16 long-listed products (the “Products”) in Japan, supply business of active pharmaceutical ingredients/bulk of the Products to third parties in Japan and outside of Japan and royalty business of the Products to LTL Pharma for 20.1 billion yen.

note: The Products sold by Astellas subsidiaries outside of Japan will be supplied by LTL Pharma to Astellas subsidiaries after the closing, and Astellas subsidiaries will maintain commercial responsibility.

Astellas has been continuously engaging in our initiatives, in anticipation of changing environments from various perspectives, with the aim of creating organizations and systems capable of resiliently responding to evolving environments and further improving quality and efficiency of operations. As one of these initiatives, Astellas executed the agreement with LTL Pharma. Astellas aims for sustainable growth by reallocating internal resources to activities that drive our competitive advantage.

LTL Pharma, a wholly-owned subsidiary of Japan Established Medicines Corporation established by Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), L.P., is a pharmaceutical company specializing in long-listed products.

The closing of the agreement is scheduled on April 28, 2017. Following the closing date, Astellas and LTL Pharma will work closely together to ensure a smooth transition of the Products to continue delivering them to patients stably after transition. Transfer of the Products will be completed by April 2020.

1. List of the Products

Products Name	Formulation	Therapeutic category
Gaster [®]	injection, tablets, D tablets, powder	treatment for peptic ulcers and gastritis
Nasea [®]	injection, OD tablets	5HT ₃ receptor antagonist-type antiemetic
Cefamezin [®]	intramuscular injection, injection, infusion kit	oral cephalosporin
Cefzon [®]	capsules, fine granules 10% for Pediatric	oral cephalosporin
Josamysin [®]	tablets	macrolide antibiotic
Josamy [®]	syrup, dry syrup	macrolide antibiotic
Sawacillin [®]	tablets, capsules, fine granules	synthetic penicillin formulation
Hypoca [®]	capsules	sustained release calcium antagonist
Lowgan [®]	tablets	hemodynamic improving type antihypertensive
Nivadil [®]	tablets	hypertension
Perdipine [®]	tablets, LA capsules, powder, injection	calcium channel blocker
Emilace [®]	tablets, fine granules	antipsychotic
Lodopin [®]	tablets, fine granules	atypical antipsychotics
Solantal [®]	tablets 100mg	analgesia • anti-inflammatory
Neurovitan [®]	tablets	mixed vitamin B
Spongel [®]	spongel	gelatin sponge for hemostasis

2. About LTL Pharma

Corporate Name: LTL Pharma Co., Ltd.

Location: Tokyo, Japan

Representative Directors: Sansei Oka (Chairman), Jiro Mizukawa (President and CEO)

Business: Manufacturing and sale of of long-listed products

Shareholders: Japan Established Medicines Corporation (100%)

3. Advisors

For the transaction, Astellas has retained JP Morgan Securities Japan Co., Ltd. as our financial advisor, and Ito & Mitomi/Morrison & Foerster LLP. (Registered Associated Offices) as our legal advisor.

The gross sales of the Products (FY2015 ending March 31, 2016): 29.0 billion yen.
There is no impact of this transfer on Astellas' financial results of the current fiscal year ending March 31, 2017.

#####

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

Cautionary Notes

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473